An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With SoC, Versus SoC Alone, in Adult Male Patients With mHSPC

Prostatic Neoplasms Clinical Trial

— PSMAddition  

Official title:

An Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care, Versus Standard of Care Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT04720157
• Other study ID #: CAAA617C12301
• Secondary ID: 2020-003968-56
• Status: Active, not recruiting
• Phase: Phase 3
• Start date: June 9, 2021
• Est. completion date: February 11, 2026

Study information

• Verified date: March 2024
• Source: Novartis
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the efficacy and safety of 177Lu-PSMA-617 in combination with Standard of Care, versus Standard of Care alone, in adult male patients with mHSPC. In this study, the SoC is defined as a combination of Androgen Receptor Directed Therapy + Androgen Deprivation Therapy. Approximately 1126 patients will be randomized in this study. As of 31-Jan-2024, 1144 participants have been enrolled in 20 countries.

Description:

In this international, open-label, prospective, phase III study, where approximately 1126 patients with treatment naïve or minimally treated PSMA-positive mHSPC will be randomized in a 1:1 ratio to receive Standard of Care (SoC) with or without the radioligand 177Lu-PSMA-617. The primary objective of the study is to determine whether the combination of 177Lu-PSMA-617 + SoC improves rPFS over that obtained by administration of SoC alone in mHSPC patients. The randomization will be stratified according to the following three factors: disease volume (high v low), age >= 70 years (yes/no), and on Previous or planned treatment (prostatectomy or radiation) to primary (prostate) tumor (yes/no). Study duration: approximately 50 months. screening period: after signing ICF, patients will be assessed for eligibility and will be scanned with 68Ga PSMA-11 to identify PSMA expression status. Following completion of all required screening procedures and verifying participant eligibility, the participant will be randomized via the interactive response technology (IRT) system. Amended protocol v02 included an option for participants to be enrolled into a separate long-term safety follow-up study, and China extension cohort (40 to 60 participants). Amended protocol v03 excluded China extension cohort and added a second 68Ga-PSMA-11 PET/CT scan at rPD. Prior treatment: - Up to 45 days of LHRH agonist/antagonists is allowed prior to ICF signature. If patient did not start the ADT prior randomization, ADT should start as soon as possible and ideally no later than 2 weeks after randomization. - Up to 45 days of ARDT is allowed prior ICF signature. If patient did not start the ARDT prior randomization, ARDT should start as soon as possible and ideally no later than 2 weeks after randomization. Patients will received ARDT as per label instructions. Randomization period: The participant will be randomized in a 1:1 ratio to receive Standard of Care (SoC) with or without the radioligand 177Lu-PSMA-617. Treatment period: Patients randomized to the investigational arm (i.e. SoC+177Lu-PSMA-617): Patients will receive SoC as per label instructions, after randomization, if not started earlier and in the time frame allowed by the protocol. Patients must begin 177Lu-PSMA-617 dosing within 14 days after randomization or as soon as possible after the product is received. 177Lu-PSMA-617 is administered at the dose of 7.4 GBq (+/- 10%), once every 6 weeks (+/- 1 week) for a planned 6 cycles. Patients randomized to the control arm will begin receiving SoC as per label instructions after randomization, if not started earlier and in the time frame allowed by the protocol. The primary endpoint of rPFS will be assessed by a centralized blinded image review committee (i.e., BIRC) using radiographic images provided by the treating physician. Participants from both arms will also undergo PET/CT scan with 68GaPSMA-11 following Centrally confirmed rPD. An end of treatment (EOT) visit will be performed when participants permanently discontinue study treatment. Cross-over period: After patients randomized to the SoC alone (i.e., control) arm experience radiographic progression (the rPFS event) as confirmed by BIRC, they will be allowed to cross-over to receive 177Lu-PSMA-617 +/- SoC per the discretion of the treating physician. If cross-over to 177Lu-PSMA-617 is selected, then 177Lu-PSMA-617 will be administered with the same dose/schedule as participants who were initially randomized to receive 177Lu-PSMA-617 as described above. Study cross-over participants for whom 177Lu-PSMA-617 is discontinued must have a second End of Treatment (EOT2) visit performed =< 7 days and enter the Post-treatment Follow-up . Post-Treatment Follow-Up (Safety, Efficacy): After treatment discontinuation, all participants will be followed for safety with a 30-day safety follow-up visit (FUP) as well as longer term safety follow-up assessments for a period of approximately 12 months. Participants who discontinue study treatment without having progressive disease confirmed by BIRC, will continue to be assessed for efficacy (efficacy follow-up) during the post-treatment follow-up period until the occurrence of their BIRC-confirmed radiographic disease progression (rPFS) event , or if the total number of protocol-defined rPFS events has occurred triggering the primary analysis, whichever occurs first. Survival Follow-Up: After study treatment discontinuation, or post-treatment follow-up period discontinuation, the participant's status will be collected every 90 days (via phone calls) as part of the survival follow-up. Every effort should be made to comply with the survival follow-up schedule and ensure collection of participant survival. The survival follow-up and the study will end when the number of OS events required for final OS analysis will be reached.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 1144
• Est. completion date: February 11, 2026
• Est. primary completion date: July 23, 2025
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

Participants eligible for inclusion in this study must meet all of the following criteria:

1. Signed informed consent must be obtained prior to participation in the study

2. Patients must be adults =18 years of age

3. Patients must have an ECOG performance status of 0 to 2

4. Patients must have a life expectancy >9 months as determined by the study investigator

5. Patients must have metastatic prostate cancer with histologically or cytologically confirmed adenocarcinoma (current or prior biopsy of the prostate and/or metastatic site)

6. Patients must have evidence of PSMA-positive disease as seen on a 68Ga-PSMA-11 PET/CT scan, and eligible as determined by the sponsor's central reader

7. Patients must have at least one documented metastatic bone and/or soft tissue/visceral

lesion documented in the following manners within 28 days prior randomization:

1. Metastatic disease to the bone (in any distribution) visible on 99Tc-MDP bone scintigraphy on either pre-ADT scans or baseline scans AND/OR

2. Lymph node metastases of any size or distribution. If lymph nodes are the only site of metastasis, then at least one must be at least 1.5 cm in short axis AND outside of the pelvis AND/OR

3. Visceral metastases of any size or distribution. If a participant has a history of visceral metastases at any time prior to randomization, he should be coded as having visceral metastases at baseline (i.e., patients with visceral metastases prior to ADT that disappear at baseline will be counted as having visceral metastases and would therefore have high volume disease for stratification purposes).

8. Patients must have adequate organ function:

• Bone marrow reserve ANC =1.5 x 109/L Platelets =100 x 109/L Hemoglobin =9 g/dL
• Hepatic Total bilirubin =2 x the institutional upper limit of normal (ULN). For patients with known Gilbert's Syndrome =3 x ULN is permitted Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) =3.0 x ULN OR =5.0 x ULN for patients with liver metastases
• Renal eGFR = 50 mL/min/1.73m2 using the Modification of Diet in Renal Disease (MDRD) equation

9. Albumin =2.5 g/dL

10. Human immunodeficiency virus (HIV)-infected patients who are healthy and have a low risk of acquired immune deficiency syndrome (AIDS)-related outcomes can participate in this trial

11. Patients must be:

Treatment naïve OR minimally treated with:

• Up to 45 days of luteinizing hormone-releasing hormone (LHRH) agonist /antagonists or bilateral orchiectomy with or without first generation anti-androgen (e.g. bicalutamide, flutamide) for metastatic prostate cancer is allowed prior to ICF signature. If given, first generation anti-androgen must be discontinued prior to start of study therapy or after 45 days whatever happens first.
• If received, prior LHRH agonist/antagonist with or without first generation anti-androgen use in the adjuvant/neo-adjuvant setting must have been discontinued > 12 months prior to ICF signature AND must not have exceeded 24 months of therapy AND must not have shown disease progression within 12 months of completing adjuvant/neo-adjuvant therapy.
• Up to 45 days of CYP17 inhibitor or ARDT exposure for metastatic prostate cancer is allowed prior to ICF signature. No CYP17 inhibitor or ARDT exposure for earlier stages of prostate cancer is allowed. Exclusion Criteria: Participants meeting any of the following criteria are not eligible for inclusion in this study.

1. Participants with rapidly progressing tumor that requires urgent exposure to taxane-based chemotherapy

2. Any prior systemic anti-prostate cancer therapy (with the exception of the drugs listed on inclusion criteria 11), including chemotherapy, Poly (adenosine diphosphate-ribose) polymerase (PARP) inhibitors, immunotherapy or biological therapy (including monoclonal antibodies).

3. Concurrent cytotoxicity chemotherapy, immunotherapy, radioligand therapy, PARP inhibitor, biological therapy or investigational therapy

4. Previous treatment with any of the following within 6 months of randomization:

Strontium-89, Samarium-153, Rhenium-186, Rhenium-188, Radium-223, hemi-body irradiation. Previous PSMA-targeted radioligand therapy is not allowed

5. Ongoing participation in any other clinical trial

6. Use of other investigational drugs within 30 days prior to day of randomization

7. Known hypersensitivity to any of the study treatments or its excipients or to drugs of similar chemical classes

8. Transfusion for the sole purpose of making a participant eligible for study inclusion

9. Participants with CNS metastases that are neurologically unstable, symptomatic, or receiving corticosteroids for the purpose of maintaining neurologic integrity. Participants with epidural disease, canal disease and prior cord involvement are allowed if those areas have been treated, are stable, and not neurologically impaired. Participants with parenchymal CNS metastasis (or a history of CNS metastasis), that have received prior therapy and are neurologically stable, asymptomatic and not receiving steroids for CNS metastases, are allowed, baseline and subsequent radiological imaging must include evaluation of the brain (magnetic resonance imaging (MRI) preferred or CT with contrast).

10. Diagnosed with other malignancies that are expected to alter life expectancy or may interfere with disease assessment. However, participants with a prior history of malignancy that has been adequately treated and who have been disease free, treatment free for more than 3 years prior to randomization, or participants with adequately treated non-melanoma skin cancer, superficial bladder cancer are eligible.

11. Concurrent serious (as determined by the Principal Investigator) medical conditions, including, but not limited to, uncontrolled infection, known active hepatitis B or C, or other significant co-morbid conditions that in the opinion of the investigator would impair study participation or cooperation. Participants with an active documented COVID-19 infection (any grade of disease severity) at time of informed consent may be included only when completely recovered (in accordance with local guidance).

12. Active clinically significant cardiac disease defined as any of the following:

• NYHA class 3/4 congestive heart failure within 6 months prior to ICF signature unless treated with improvement and echocardiogram or MUGA demonstrates EF > 45% with improvement in symptoms to class < 3.
• History or current diagnosis of ECG abnormalities indicating significant risk of safety for participants in the study such as: Concomitant clinically significant cardiac arrhythmias, e.g. sustained ventricular tachycardia, complete left bundle branch block, high-grade atrioventricular (AV) block (e.g., bifascicular block, Mobitz type II and third degree AV block)
• History of familial long QT syndrome or known family history of Torsades de Pointes
• Cardiac or cardiac repolarization abnormality, including any of the following:

History of myocardial infarction (MI), angina pectoris, or coronary artery bypass graft (CABG) within 6 months prior to ICF signature

13. History of somatic or psychiatric disease/condition that may interfere with the objectives and assessments of the study

14. Symptomatic cord compression, or clinical or radiologic findings indicative of impending cord compression

15. Any condition that precludes raised arms position

16. Unmanageable concurrent bladder outflow obstruction or urinary incontinence. Note:

participants with bladder outflow obstruction or urinary incontinence, which is manageable and controlled with best available standard of care (incl. pads, drainage) are allowed.

17. Sexually active males unwilling to use a condom during intercourse while taking study treatment and for 14 weeks after stopping study treatment. A condom is required for all sexually active male participants to prevent them from fathering a child AND to prevent delivery of study treatment via seminal fluid to their partner. In addition, male participants must not donate sperm for the time period specified above. If local regulations deviate from the contraception methods listed above to prevent pregnancy, local regulations apply and will be described in the ICF

Related Conditions & MeSH terms

• Prostatic Neoplasms

Intervention

Drug:
• 177Lu-PSMA-617
administered intravenously once every 6 weeks (1 cycle) for 6 cycles
• 68Ga-PSMA-11
Intravenous dose of approx. 150 Megabecquerel (MBq) at screening and at time of centrally confirmed rPD
• ARDT
Administered orally on a continuous basis as per package insert and guideline
• ADT
ADT are administered as per physician order

Locations

Country	Name	City	State
Austria	Novartis Investigative Site	Innsbruck	Tyrol
Austria	Novartis Investigative Site	Linz
Austria	Novartis Investigative Site	Wien
Belgium	Novartis Investigative Site	Bruxelles
Belgium	Novartis Investigative Site	Gent
Canada	Novartis Investigative Site	Hamilton	Ontario
Canada	Novartis Investigative Site	Montreal	Quebec
Canada	Novartis Investigative Site	Montreal	Quebec
Canada	Novartis Investigative Site	Montreal	Quebec
Canada	Novartis Investigative Site	Quebec
Canada	Novartis Investigative Site	Sherbrooke	Quebec
Canada	Novartis Investigative Site	Toronto	Ontario
Canada	Novartis Investigative Site	Vancouver	British Columbia
China	Novartis Investigative Site	Beijing
China	Novartis Investigative Site	Chengdu	Sichuan
China	Novartis Investigative Site	Guangzhou
China	Novartis Investigative Site	Nanjing
China	Novartis Investigative Site	Nanjing	Jiangsu
China	Novartis Investigative Site	Shanghai	Shanghai
China	Novartis Investigative Site	Shanghai
China	Novartis Investigative Site	Shanghai
China	Novartis Investigative Site	Shanghai
China	Novartis Investigative Site	Tianjin
China	Novartis Investigative Site	Xian	Shanxi
Czechia	Novartis Investigative Site	Olomouc	CZE
Czechia	Novartis Investigative Site	Praha 5
Denmark	Novartis Investigative Site	Copenhagen
France	Novartis Investigative Site	Bordeaux Cedex
France	Novartis Investigative Site	Clermont-Ferrand
France	Novartis Investigative Site	Lyon
France	Novartis Investigative Site	Montpellier
France	Novartis Investigative Site	Nantes Cedex 1
France	Novartis Investigative Site	Paris
France	Novartis Investigative Site	Paris
France	Novartis Investigative Site	Strasbourg
France	Novartis Investigative Site	Vandoeuvre
France	Novartis Investigative Site	Villejuif
Germany	Novartis Investigative Site	Essen
Germany	Novartis Investigative Site	Koeln
Germany	Novartis Investigative Site	Muenchen
Germany	Novartis Investigative Site	Muenster
Germany	Novartis Investigative Site	Rostock
Germany	Novartis Investigative Site	Wuerzburg
Japan	Novartis Investigative Site	Bunkyo ku	Tokyo
Japan	Novartis Investigative Site	Chiba
Japan	Novartis Investigative Site	Chuo ku	Tokyo
Japan	Novartis Investigative Site	Fukuoka
Japan	Novartis Investigative Site	Fukuoka city	Fukuoka
Japan	Novartis Investigative Site	Fukushima city	Fukushima
Japan	Novartis Investigative Site	Kitaadachi-gun	Saitama
Japan	Novartis Investigative Site	Kobe-city	Hyogo
Japan	Novartis Investigative Site	Kumamoto City	Kumamoto
Japan	Novartis Investigative Site	Kyoto
Japan	Novartis Investigative Site	Nagoya	Aichi
Japan	Novartis Investigative Site	Okayama-city	Okayama
Japan	Novartis Investigative Site	Sapporo city	Hokkaido
Japan	Novartis Investigative Site	Suita	Osaka
Japan	Novartis Investigative Site	Yamagata
Japan	Novartis Investigative Site	Yokohama-city	Kanagawa
Korea, Republic of	Novartis Investigative Site	Seoul	Korea
Korea, Republic of	Novartis Investigative Site	Seoul
Korea, Republic of	Novartis Investigative Site	Seoul
Netherlands	Novartis Investigative Site	Delft
Netherlands	Novartis Investigative Site	Maastricht
Netherlands	Novartis Investigative Site	Nijmegen	Netherland
Netherlands	Novartis Investigative Site	Utrecht
Poland	Novartis Investigative Site	Gliwice	Slaskie
Poland	Novartis Investigative Site	Krakow
Poland	Novartis Investigative Site	Warszawa
Singapore	Novartis Investigative Site	Singapore
Singapore	Novartis Investigative Site	Singapore
Spain	Novartis Investigative Site	Barcelona	Catalunya
Spain	Novartis Investigative Site	Barcelona	Catalunya
Spain	Novartis Investigative Site	El Palmar	Murcia
Spain	Novartis Investigative Site	Hospitalet de LLobregat	Catalunya
Spain	Novartis Investigative Site	Madrid
Spain	Novartis Investigative Site	Madrid
Spain	Novartis Investigative Site	Madrid
Spain	Novartis Investigative Site	Madrid
Spain	Novartis Investigative Site	Madrid
Spain	Novartis Investigative Site	Sabadell	Barcelona
Spain	Novartis Investigative Site	Valencia
Sweden	Novartis Investigative Site	Goteborg
Sweden	Novartis Investigative Site	Lund
Sweden	Novartis Investigative Site	Stockholm
Switzerland	Novartis Investigative Site	Bern
Switzerland	Novartis Investigative Site	Lausanne
Taiwan	Novartis Investigative Site	Taipei
Taiwan	Novartis Investigative Site	Taoyuan
United Kingdom	Novartis Investigative Site	Belfast
United Kingdom	Novartis Investigative Site	Cambridge
United Kingdom	Novartis Investigative Site	Glasgow
United Kingdom	Novartis Investigative Site	London
United Kingdom	Novartis Investigative Site	London
United Kingdom	Novartis Investigative Site	London
United Kingdom	Novartis Investigative Site	Middlesbrough	Yorkshire
United Kingdom	Novartis Investigative Site	Sutton	Surrey
United States	University of New Mexico .	Albuquerque	New Mexico
United States	Uni of Michigan Health System	Ann Arbor	Michigan
United States	Uni Cancer and Blood Center, LLC	Athens	Georgia
United States	Anschutz Medical Center Anschutz Medical Campus	Aurora	Colorado
United States	Sidney Kimmel CCC At JH .	Baltimore	Maryland
United States	Dana Farber Cancer Institute Dana-Farber Cancer Institute_	Boston	Massachusetts
United States	Montefiore Medical Center	Bronx	New York
United States	Levine Cancer Institute Oncology Dept	Charlotte	North Carolina
United States	University of Virginia Medical Center	Charlottesville	Virginia
United States	Northwestern University Northwestern 6	Chicago	Illinois
United States	Rush University Medical Center .	Chicago	Illinois
United States	University of Chicago	Chicago	Illinois
United States	Cleveland Clinic Foundation .	Cleveland	Ohio
United States	The Ohio State University Comprehensive Cancer Center .	Columbus	Ohio
United States	Dallas VA Medical Center	Dallas	Texas
United States	Texas Oncology Texas Oncology - Plano West	Dallas	Texas
United States	Univ of Texas Southwest Med Center	Dallas	Texas
United States	Duke Univ Medical Center .	Durham	North Carolina
United States	Parkview Research Center .	Fort Wayne	Indiana
United States	Hartford Hospital .	Hartford	Connecticut
United States	Penn State Hershey Medical Center .	Hershey	Pennsylvania
United States	Hines VA Hospital .	Hines	Illinois
United States	The Queens Medical Centre	Honolulu	Hawaii
United States	MD Anderson .	Houston	Texas
United States	UT Health Science Center	Houston	Texas
United States	Indiana University Simon Cancer Center	Indianapolis	Indiana
United States	University of Mississippi Med Ctr .	Jackson	Mississippi
United States	Cancer Specialists of North Florida	Jacksonville	Florida
United States	Mayo Clinic Jacksonville	Jacksonville	Florida
United States	University of California San Diego - Moores Cancer Center	La Jolla	California
United States	Rocky Mountain Cancer Centers Rocky Mountain Cancer Centers	Longmont	Colorado
United States	University Of California LA .	Los Angeles	California
United States	VA Greater LA Healthcare System	Los Angeles	California
United States	Baptist Health Medical Group .	Miami	Florida
United States	University Of Miami .	Miami	Florida
United States	Medical College of Wisconsin .	Milwaukee	Wisconsin
United States	University of Minnesota	Minneapolis	Minnesota
United States	Carolina Urologic Res Center, LLC	Myrtle Beach	South Carolina
United States	Ochsner Clinic Foundation .	New Orleans	Louisiana
United States	Tulane Cancer Center	New Orleans	Louisiana
United States	Memorial Sloan Kettering Cancer Ctr	New York	New York
United States	Weill Cornell Medical College	New York	New York
United States	Virginia Oncology Associates .	Norfolk	Virginia
United States	Nebraska Cancer Specialists	Omaha	Nebraska
United States	Urology Cancer Center PC	Omaha	Nebraska
United States	St. Joseph Hospital Center for Cancer Prevention	Orange	California
United States	Univ Cali Irvine ALS Neuromuscular .	Orange	California
United States	VA Palo Alto Health Care System .	Palo Alto	California
United States	Florida Cancer Affiliates	Panama City	Florida
United States	Thomas Jefferson Univ Hosp	Philadelphia	Pennsylvania
United States	Univ of Pittsburgh Cancer Institute SC-3	Pittsburgh	Pennsylvania
United States	Oregon Health Sciences University .	Portland	Oregon
United States	Onco Hemato Asso of SE Virginia Roanoke Loc	Roanoke	Virginia
United States	Mayo Clinic	Rochester	Minnesota
United States	Univ of Rochester Cancer Ctr .	Rochester	New York
United States	Pharmacy Beaumont Hospital	Royal Oak	Michigan
United States	St. Louis University .	Saint Louis	Missouri
United States	VA St Louis Health Care System	Saint Louis	Missouri
United States	Washington Uni School Of Medicine .	Saint Louis	Missouri
United States	UT Health San Antonio Mays Cancer Center .	San Antonio	Texas
United States	Sansum Clinic SC	Santa Barbara	California
United States	Providence Saint Johns Health Ctr	Santa Monica	California
United States	Mayo Clinic - Arizona Mayo Clinic Hospital	Scottsdale	Arizona
United States	Swedish Medical Center .	Seattle	Washington
United States	Stanford University Medical Center .	Stanford	California
United States	Georgetown University Lombardi	Washington	District of Columbia
United States	VA Medical Center	Washington	District of Columbia

Sponsors (3)

Lead Sponsor	Collaborator
Novartis Pharmaceuticals	Alliance Foundation Trials, LLC., RTOG Foundation, Inc.

Countries where clinical trial is conducted

United States,  Austria,  Belgium,  Canada,  China,  Czechia,  Denmark,  France,  Germany,  Japan,  Korea, Republic of,  Netherlands,  Poland,  Singapore,  Spain,  Sweden,  Switzerland,  Taiwan,  United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Radiographic Progression Free Survival (rPFS)	rPFS is defined as the time of radiographic progression by Prostate Cancer Working Group 3 (PCWG3)-modified RECIST V1.1 as assessed by blinded independent central review, or death	From date of randomization until date of radiographic progression or date of death from any cause, whichever comes first, assessed up to 50 months (estimated final OS analysis)
Secondary	Overall Survival (OS)	OS is defined as time to death for any cause	From date of randomization until date of death from any cause, assessed up to 50 months (estimated final OS analysis)
Secondary	Prostate-specific antigen 90 (PSA90) response	PSA90 response is defined as the proportion of patients who have a more/equal 90% decrease in PSA from baseline, it will be calculated at 12, 24 and 48 months	From date of randomization till 30 days safety fup, assessed up to 50 months (estimated final OS analysis)
Secondary	time to development of mCRPC	Time to development of mCRPC is defined as the time from date of randomization to disease progression despite androgen deprivation therapy (ADT) presenting as either a continuous rise in serum prostate-specific antigen (PSA) levels, the progression of pre existing disease, and/or the appearance of new metastases.	From date of randomization till End Of Treatment (EOT) or death, which ever happen first, assessed up to 50 months (estimated final OS analysis)
Secondary	Progression Free Survival (PFS)	PFS is defined as the time from date of randomization to the date of first documented progression by investigator assessment (radiographic progression, clinical progression, PSA progression) or death from any cause, whichever occurs first	From date of randomization until date of progression or date of death from any cause, whichever come first, assessed up to 50 months (estimated final OS analysis)
Secondary	second Progression Free Survival (PFS2)	PFS2 is defined as time from date of randomization to the first documented progression by investigator assessment (radiographic progression, clinical progression, PSA progression) on next-line therapy or death from any cause, whichever occurs first.	From date of randomization until date of second progression or date of death from any cause, whichever comes first, assessed up to 50 months (estimated final OS analysis)
Secondary	Change in nadir level of PSA lower than 0.2 ng/ml	Proportion of patients with PSA < 0.2 ng/mL at months 12, 24 and 48 months	From date of randomization till 30 days safety fup, whichever occur first, assessed up to 50 months (estimated final OS analysis)
Secondary	Time to radiographic soft tissue progression (TTSTP)	TTSTP is defined as time from randomization to radiographic soft tissue progression per PCWG3-modified RECIST v1.1 (Soft Tissue Rules of Prostate Cancer Working Group modified Response Evaluation Criteria in Solid Tumors Version 1.1) as assessed by Blinded Independent Central Review (BICR)	From date of randomization until date of soft tissue radiographic progression or date of death from any cause, whichever comes first, assessed up to 50 months (estimated final OS analysis)
Secondary	Time to first symptomatic skeletal event (SSE).	Time to SSE (TTSSE) is defined as date of randomization to the date of first new symptomatic pathological bone fracture, spinal cord compression, tumor-related orthopedic surgical intervention, requirement for radiation therapy to relieve bone pain or death from any cause, whichever occurs first	From date of randomization till EOT or death, whichever happens first, assessed up to 50 months (estimated final OS analysis)
Secondary	Overall Response Rate (ORR)	ORR is defined as the proportion of participants with best overall response of complete response or partial response in soft tissue as per BIRC and according to PCWG3 modified RECIST 1.1	From date of randomization till 30 days safety fup, assessed up to 50 months (estimated final OS analysis)
Secondary	Disease Control Rate (DCR)	DCR is defined as the proportion of participants with best overall response of complete response or partial response or Stable disease in soft tissue as per BIRC and according to PCWG3 modified RECIST 1.1	From date of randomization till 30 days safety fup, assessed up to 50 months (estimated final OS analysis)
Secondary	Duration of Response (DOR)	DOR is defined as the duration of time between the date of first documented response (CR or PR) in soft tissue as per BIRC and according to PCWG3 modified RECIST 1.1, and the date of first documented progression or death due to any cause	From date of randomization until date of progression or date of death from any cause, whichever come first, assessed up to 50 months (estimated final OS analysis)
Secondary	Time to Response (TTR)	TTR is defined as the time from the date of randomization to the date of first documented response (CR or PR).	From date of randomization till 30 days safety fup, assessed up to 50 months (estimated final OS analysis)
Secondary	Functional Assessment of Cancer Therapy - Prostate (FACT-P) Questionnaire	FACT-P assesses symptoms/problems related to prostate carcinoma and its treatment. It is a combination of the FACT-General + the Prostate Cancer Subscale (PCS). The FACT-General (FACT-G) is a 27 item Quality of Life (QoL) measure that provides a total score as well as subscale scores: Physical (0-28), Functional (0-28), Social (0-28), and Emotional Well-being (0-24). The total score range is between 1-108, higher scores indicates better for total score and subscale scores. PCS is a 12-item prostate cancer subscale that asks about symptoms and problems specific to prostate cancer (Range 0-48, higher scores better). The FACT-P total score is the sum of all 5 subscale scores of the FACT-P questionnaire and ranges from 0-156. Higher scores indicate higher degree of functioning and better quality of life.	From randomization up till 30 day safety Follow-up or week 48 of long term Follow-up for patients prematurely discontinued, assessed up to 50 months (estimated final OS analysis)
Secondary	European Quality of Life ( EuroQoL) -5 Domain 5 Level Scale (EQ-5D-5L)	EQ-5D-5L is a standardized participant completed questionnaire that measures health-related quality of life and translates that score into an index value or utility score. EQ-5D-5L consists of two components: a health state profile and an optional visual analogue scale (VAS). EQ-5D health state profile is comprised of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: 1= no problems, 2= slight problems, 3=moderate problems, 4= severe problems, and 5= extreme problems. Higher scores indicated greater levels of problems across each of the five dimensions.	From screening up till 30 day safety follow-up or week 48 of long term follow up for patient prematurely discontinued, assessed up to 50 months (estimated final OS analysis)
Secondary	Brief Pain Inventory-short Form (PBI-SF)	The BPI-SF is a publicly available instrument to assess the pain and includes severity and interference scores. BPI-SF is an 11-item self report questionnaire that is designed to assess the severity and impact of pain on daily functions of a participant. Pain severity score is a mean value for BPI-SF questions 3, 4, 5 and 6 (questions inquiring about the extent of pain, where the extent is ranked from 0 [no pain] to 10 [pain as bad as you can imagine]). Pain severity progression is defined as an increase in score of 30% or greater from baseline without decrease in analgesic use.	From screening up till 30 day safety follow-up or week 48 of long term follow up for patient prematurely discontinued, assessed up to 50 months (estimated final OS analysis)
Secondary	Number of participants with Treatment Emergent Adverse Events	The distribution of adverse events (AE) will be done via the analysis of frequencies for treatment emergent Adverse Event (TEAEs), Serious Adverse Event (TESAEs) and Deaths due to AEs, through the monitoring of relevant clinical and laboratory safety parameters.	From randomization till 30 days safety follow-up, assessed up to 50 months (estimated final OS analysis)